Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1477-9560

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series ; volume:16 ; number:1 ; day:19 ; month:12 ; year:2018 ; pages:1-7 ; date:12.2018
Thrombosis journal ; 16, Heft 1 (19.12.2018), 1-7, 12.2018

Classification: Medizin, Gesundheit

Creator: Greenfield, Graeme
McMullin, Mary Frances

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12959-018-0187-z

URN: urn:nbn:de:101:1-2019011622044069926526

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 2025-08-14T10:58:36+0200

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Greenfield, Graeme
McMullin, Mary Frances
SpringerLink (Online service)

Other Objects (12)

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Related objects

Reset password